Published 2 years ago

Switch to Prasugrel Safe After PCI in East Asian ACS Patients

Summary by Ground News

Korean acute coronary syndrome (ACS) patients who were started and remained on prasugrel after percutaneous coronary intervention (PCI) did not have rates of major adverse cardiac and cerebrovascular events (MACCE) any different than those started on another P2Y12 inhibitor. The major cause of switches to pr asugrel from other antiplatelet therapies, like clopidogrel, was the necessity for a more potentAntiplatelet agent.

0 Articles

All

Left

Center

Right

Medscape

Switch to Prasugrel Safe After PCI in East Asian ACS Patients

Dual antiplatelet therapy with prasugrel seemed as safe and effective as primary treatment and as a substitute for other P2Y12 inhibitors in a real-world Korean registry.

2 years ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.